Unecritinib
Relapsed/Refractory Anaplastic Large Cell Lymphoma (ALCL)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Small moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
52 Active assets in the Relapsed/Refractory Anaplastic Large Cell Lymphoma (ALCL) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
(+)-VINCRISTINE Seagen Inc. | Phase 4 | BBB |
Crizotinib Pfizer | Phase 4 | BBB |
Inno-206 City of Hope Medical Center | Phase 4 | BBB |
Brentuximab Vedotin Seagen Inc. | Phase 3 | BBB |
Cyclophosphamide National Cancer Institute (NCI) | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Unecritinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →